Brain metastases …

Mariza Daras MD

Neuro-Oncology

Updated 04.02.2023
Released 04.07.1994
Expires For CME 04.02.2026

Brain metastases

Author: Mariza Daras MD

See Contributor Disclosures

Editor: Rimas V Lukas MD

Brain metastases

In This Article

Quick Link

Introduction

Overview

Metastatic brain tumors arising from systemic cancer affect approximately 150,000 people in the United States each year (149). They are one of the most common neurologic complications of cancer, and their incidence is likely increasing with improved diagnostic techniques and more effective systemic treatments, leading to longer survival. Brain metastases have a potentially devastating effect on quality of life and patient survival. Developments in treatment of patients with brain metastases include stereotactic radiosurgery following surgical resection, molecularly targeted agents, and immunotherapy. The author of this clinical article summarizes the clinical features of brain metastases and provides an updated summary and critique of currently available treatments.

Key points

	• Metastasis to the brain parenchyma is the single most frequent neurologic complication of several common neoplasms, including lung cancer, breast cancer, and melanoma.
	• Brain metastases often have a devastating impact on patients' quality of life and are fatal if not controlled.
	• Treatment options for patients with brain metastases include surgical resection, whole-brain radiation therapy, stereotactic radiosurgery, and in some cases chemotherapy, immunotherapy, or molecularly targeted therapy.
	• The management of patients with brain metastases needs to be individualized based on the primary tumor type, number, size, and location of brain metastases, status of the systemic tumor, patients' neurologic and overall performance status, and anticipated duration of survival.

Historical note and terminology

Brain metastases are neoplasms that originate in tissues or organs outside the brain and spread to involve the brain parenchyma. Brain metastases can occur in conjunction with metastases to other parts of the central nervous system, such as the dura or leptomeninges. Metastases to the brain may be single or multiple. The phrase "single brain metastasis" refers to an apparent single cerebral lesion and makes no implication regarding the extent of cancer elsewhere in the body. The phrase "solitary brain metastasis" is used to describe the relatively rare occurrence of a single brain metastasis that is the only known site of metastatic cancer in the body. Synchronous brain metastases are present at the time of the initial systemic tumor diagnosis, whereas metachronous metastases develop later in the course of patients' disease.

Historically, patients with brain metastases had dismal outcomes, and treatment recommendations were limited to those with palliative intent. In 1926 Grant reported the first series of patients given surgical treatment for single brain metastases (71). Radiation therapy for the palliation of brain metastases was introduced in the 1950s. However, it was not until the publication of several prospective studies that demonstrated survival benefit of surgery or stereotactic radiosurgery (SRS) with whole brain radiation (WBRT) that paradigms changed (128; 127; 177). With an evolving understanding of the biology of brain metastases, as well as a more nuanced understanding of subtype specific natural histories, systemic treatment options have also had a significant impact on approaches to treatment for patients with brain metastases.

Clinical manifestations

Presentation and course

• Many patients with brain metastases will manifest neurologic symptoms, the most common being headaches.

Many patients with brain metastases have some neurologic symptoms throughout the course of their illness. The clinical presentation of brain metastases is similar to that of other mass lesions in the brain and is determined by the size, location, and number of lesions. Symptoms can progress quickly and evolve over a few weeks. Most patients have a combination of "generalized" nonlocalizable symptoms (eg, headache, altered mental status, cognitive impairment) as well as "focal" signs and symptoms determined by the anatomic location. Generalized symptoms occur in patients with mass effect and increased intracranial pressure or in patients with multiple bilateral metastases. Headache is the single most common symptom of brain metastases, although a minority of patients never develop headache. Approximately 15% of patients have seizures as a presenting symptom of the metastasis, with another 10% of patients developing seizures subsequently. This is a lower seizure incidence than that which is observed with most primary brain tumors. Anywhere from 5% to 10% of patients present with acute neurologic symptoms caused by hemorrhage of, or sudden expansion of, the metastasis. Hemorrhage of a metastasis is particularly common with choriocarcinoma, renal cell carcinoma, and melanoma. Because brain metastases present varied signs and symptoms, their presence should be suspected in all patients with known systemic cancer in whom any new neurologic findings develop (46). As central nervous system imaging is more frequently performed, it is likely that asymptomatic brain metastases are being detected with increasing frequency.

Prognosis and complications

	• For most patients, treatment of brain metastases prevents death due to neurologic causes and overall survival is determined by systemic cancer control.
	• To estimate prognosis for patients with brain metastases and to help guide decisions regarding the appropriate aggressiveness of therapy, prognostication indices have been developed.

Brain metastases are generally associated with a poor prognosis (as are most other manifestations of stage IV cancer), regardless of treatment. Historically, patients who receive no treatment for brain metastases or those treated only with corticosteroids generally survive 1 to 2 months and die as a direct result of the brain lesions. Historically, overall median survival is 3 to 8 months among patients who receive some type of anti-tumor treatment for brain metastases (156; 126). More recent data, however, have shown improvement in survival with advances in systemic therapy and the median ranges from 8 to 16 months and beyond (159; 160). For most patients, treatment of the brain metastases prevents death due to neurologic causes, so the overall survival prognosis becomes largely dependent on control of the systemic cancer. However, uncontrolled or recurrent brain metastases remain the sole or contributing cause of death in a significant proportion of patients with melanoma, non-small cell lung cancer, and breast cancer.

Several key factors play a role in patient outcomes, including age, extent of primary disease control, rate of brain metastases development (ie brain metastases velocity), presence of extracranial metastases or leptomeningeal disease, performance status (typically measured by the Karnofsky Performance scale), extent of intracranial disease, and histology of the primary tumor. To more reliably estimate prognosis for patients with brain metastases and to help guide decisions regarding the appropriate aggressiveness of therapy, prognostication indices have been developed. These include the recursive partitioning analysis (RPA) score, graded prognostic assessment (GPA), and disease-specific GPA (dsGPA), among others.

In 1997, Gaspar and colleagues reported a recursive partitioning analysis of survival data from more than 1200 patients with brain metastases treated with whole brain radiation in Radiation Therapy Oncology Group (RTOG) protocols. Three RPA classes with significantly different survival were identified (see Table 1). The patient population utilized to create these RPA classes may not reflect the contemporary brain metastases population encountered in oncology and neuro-oncology clinics.

Table 1. Recursive Partitioning Analysis (RPA) Classes for Persons with Brain Metastases

	Class 1	Class 2	Class 3
Karnofsky performance score	> 70	> 70	< 70
Primary (systemic) tumor status	controlled	uncontrolled	uncontrolled
Age in years	< 65	> 65	> 65
Extracranial metastases	none	present	present

Median survival for patients in RPA Classes 1, 2, and 3 was 7.1 months, 4.2 months, and 2.3 months, respectively (63). The predictive value of this RPA classification scheme was validated in a subsequent RTOG study of whole brain radiation therapy (62), as well as in several series of patients treated with stereotactic radiosurgery (37; 142).

A newer prognostic scheme for patients with brain metastases eliminates the subjective judgment of "controlled" or "uncontrolled" systemic tumor and incorporates data correlating overall survival with the number of brain metastases. Patients are assigned a subscore for each of four key prognostic factors and then a total graded prognostic assessment (GPA) score ranging from 0.0 to 4.0 (see Table 2).

Table 2. Graded Prognostic Assessment (GPA) for Persons with Brain Metastases

	Score 0.0	Score 0.5	Score 1.0
Age in years	> 60	50 to 60	< 50
Karnofsky performance score	< 70	70 to 80	90 to 100
Number of brain metastases	> 3	2 or 3	1
Extracranial metastases	present	--	absent

Retrospectively applying the GPA to nearly 2000 patients from RTOG studies defined four patient groups with significantly different median survivals (GPA 0.0 to 1.0, 2.6 months; GPA 1.5 to 2.5, 3.8 months; GPA 3.0, 6.9 months; GPA 3.5 to 4.0, 11.0 months) (155). The majority of patients in these studies had lung cancer. Unfortunately, up to one half of patients with newly diagnosed brain metastases fall into a poor prognostic category (total GPA score 0.0 to 1.0).

The predictive value of the individual prognostic factors in the GPA varies somewhat among different primary tumor types, leading to "disease-specific GPA" (156; 157). Molecular markers such as EGFR mutations and ALK rearrangements have been incorporated to create a more specific lung cancer GPA (161). This is similar to the prior incorporation of hormone receptor and HER-2 status in the GPA for breast cancer patients (158). Disease-specific GPA is currently used in several clinical trials for patient eligibility and stratification.

Another method for estimating individual patient prognosis is the use of nomograms (13; 112), which in some studies outperformed the disease-specific GPA. Finally, the use of brain metastases velocity, the annualized rate at which a patient develops new brain metastases, can be used to predict the likelihood of death due to neurologic causes (56; 115). As would be assumed, patients who develop numerous metastases quickly have a higher likelihood of having their neurologic CNS disease burden drive mortality.

Clinical vignette

After presenting with a syncopal episode, a 55-year-old man was diagnosed with metastatic small cell lung cancer, involving lung, lymph nodes, bone, and adrenal gland. Initial staging showed no evidence of brain involvement, and he began treatment with cisplatin/etoposide and planned for prophylactic cranial irradiation. After four months of treatment and a systemic response, he underwent an MR brain for radiation planning, which demonstrated at least 20 supra and infratentorial metastases, some with intratumoral hemorrhage.

MRI showing multiple brain metastases

Gadolinium-enhanced MR scan showing multiple brain metastases from small cell lung cancer. (Contributed by Dr. Mariza Daras.)

He experienced no major neurologic symptoms and completed 3000 cGy whole brain radiation therapy. His therapy was subsequently changed to ipilimumab and nivolumab for progressive systemic disease. However, after 2 months, he developed superior vena cava syndrome from worsening disease in the chest and tumor encasement of the pulmonary artery. MRI brain also showed a mixed response, with growth of two previously treated metastases and a new one, which were targeted with stereotactic radiosurgery. He remained neurologically asymptomatic and continued treatment with single agent paclitaxel. Within 2 months, repeat imaging of the brain showed numerous new and increased metastases, and treatment was changed to temozolomide. However, after one month, the disease progression in the brain continued, which systemically prompted a change to etoposide, carboplatin, and bevacizumab. He experienced minimal neurologic symptoms aside from fatigue related to treatment and some mild difficulty with concentration, and an MR brain demonstrated an initial response. Five months later, however, he experienced a generalized seizure after which he had progressively worsening confusion, lethargy, and gait instability. MR brain confirmed progression of multiple brain metastases with peritumoral edema, and CT for staging showed systemic progression as well. The decision was made to discontinue tumor directed therapies and only continue steroids and seizure medications. He died 2 years after his initial diagnosis.

Biological basis

Etiology and pathogenesis

	• Brain metastases are caused by hematogenous spread of circulating tumor cells.
	• There are large differences in the propensity of various neoplasms to metastasize to and thrive in the brain parenchyma.
	• Complex interactions between the primary tumor site, metastatic cells, and the tumor microenvironment are crucial for growth before and after seeding of metastatic cells.
	• Cancer cells metastasizing to the brain are often molecularly distinct from the primary tumor, harboring driver mutations not present in their respective primary tumors. This is termed branched evolution.

Brain metastases are caused by the spread of tumor cells to the brain from tissues located outside the central nervous system.

Most tumor cells reach the brain by hematogenous spread, nearly always via the arterial circulation. Within the brain, metastases are most commonly found in the area directly beneath the gray-white junction. The predominance of metastases here is due to a change in the size of blood vessels at this point; the narrowed vessels act as a trap for emboli. Brain metastases also tend to be more common at the terminal "watershed areas" of arterial circulation (the zones on the border of or between the territories of the major cerebral vessels). The distribution of metastases among the large subdivisions of the central nervous system follows roughly the relative weight of and blood flow to each area. Approximately 80% of brain metastases are located in the cerebral hemispheres, 15% in the cerebellum, and 5% in the brainstem.

There are large differences in the propensity of various neoplasms to metastasize to the brain parenchyma. The highest prevalence of brain metastases occurs in patients with germ cell tumors, melanoma, and small cell lung carcinoma. Breast carcinoma, non-small cell lung cancers, and renal carcinoma have an intermediate propensity to metastasize to the brain. Among patients with breast carcinoma, a higher risk of developing brain metastases is associated with overexpression of the epidermal growth factor receptor or of the HER2 (ErbB-2) growth factor receptor, or with absent expression of HER2, estrogen receptors, and progesterone receptors ("triple-negative tumors") (88; 44). Mutations in EGFR and KRAS in non-small cell lung cancer are associated with a high prevalence of brain dissemination in non-small cell lung cancer (178; 117). Brain metastases are disproportionately uncommon among patients with carcinoma of the prostate and GI tract. Sarcomas do not commonly spread to the brain, despite their high propensity to metastasize to the lungs.

Studies are elucidating the molecular pathophysiology of brain metastases and the molecular basis for the differences in "neurotropism" among various systemic tumors. To successfully form brain metastases, tumor cells must attach to and penetrate microvessel endothelium, degrade the extracellular matrix, and respond to autocrine and brain-derived survival and growth factors. Complex interactions between the primary tumor site, metastatic cells, and the tumor microenvironment are crucial for growth before and after seeding (175; 133; 26). The role of astrocytes in metastases has been elucidated more recently, and coupling of metastatic cells with astrocytes through gap junctions can confer chemoresistance and enhance tumor growth (35). Immunosuppressive elements of the metastatic microenvironment through tumor associated macrophages and regulatory T cells, also play a key role (91). In addition, cancer cells metastasizing to the brain are often molecularly distinct from the primary tumor, harboring driver mutations absent in their respective primary tumors. Some of these genetic alterations include mutations in CDKN2A and PIK3CA, loss of PTEN, amplification of ERBB2, and activating proto-oncogene KRAS mutations (20).

Epidemiology

	• Any neoplasm is capable of metastasizing to the brain, although two thirds of all adult patients have lung cancer, breast cancer, or melanoma.
	• There is an increasing incidence of brain metastases as the sole or early site of relapse due to more effective therapies for systemic disease.

Approximately 150,000 patients in the United States develop symptomatic brain metastases each year, making them the most common intracranial malignancies. Approximately 60% to 80% of patients that present with brain metastases also have synchronous systemic metastatic disease, with pulmonary involvement being the most frequent (170). Any neoplasm is capable of metastasizing to the brain, although two thirds of all adult patients have lung cancer, breast cancer, or melanoma. Bronchogenic carcinoma is the single most common source of brain metastases in adults, accounting for 30% to 50% of all cases (46). Lung carcinomas are also the tumors most likely to spread to the brain in the absence of other systemic metastases. In most series of brain metastases breast carcinoma and melanoma each account for 10% to 20% of cases. In up to 10% of patients presenting with brain metastases, no primary tumor can be initially identified despite investigation. The primary tumor site, if eventually detected, is usually the lung (124).

For some tumors, there is an increasing incidence of brain metastases as the sole or early site of relapse due to more effective therapies for systemic disease. This is especially true for non-small cell lung cancer and for breast carcinomas that overexpress HER-2. Women with breast carcinoma treated with the anti-HER-2 monoclonal antibody trastuzumab have been shown to have a 25% to 35% cumulative lifetime incidence of brain metastases, and about a 10% incidence of isolated brain metastases as the sole site of tumor progression (96; 24). This may at least in part reflect an "unmasking" of occult brain metastases that are protected by the inability of trastuzumab to cross the blood-brain barrier (103). However, data are conflicting as three large, randomized phase 3 clinical trials did not show a significant difference in the incidence of brain metastases in HER-2 positive patients treated with or without trastuzumab (138; 151; 96).

Brain metastases in children occur in approximately 5% of patients with solid tumors, and most often arise from sarcomas (osteogenic sarcoma, rhabdomyosarcoma, and Ewing sarcoma) and neuroblastoma (19; 87).

Prevention

• At this time, there are no standard prophylactic therapies for prevention of brain metastases in patients with solid tumors with the exception of patients with limited-stage small cell lung cancer.

Prevention of brain metastases has mainly been focused on patients with small cell lung cancer, because of the high prevalence of brain metastases after systemic treatment and the high degree of sensitivity of this tumor to radiation. For patients with limited-stage small cell lung carcinoma who achieve a complete remission after initial systemic therapy, the consensus results of several randomized studies indicate that prophylactic whole brain radiation therapy significantly reduces the cumulative incidence of brain metastases (from 50% to 60% to 25% to 30%) and significantly improves overall survival (05; 72; 08). Prophylactic cranial irradiation may also be beneficial for a subset of patients with initially extensive small cell lung carcinoma who have a good response to initial chemotherapy (150). Deferring prophylactic whole brain radiation therapy until after completion of induction systemic chemotherapy is believed to reduce the risk of long-term neurotoxicity. The most commonly used dose for prophylactic whole brain radiation therapy is 2500 cGy in 10 daily fractions. Higher doses are not more effective.

Although there has been an increasing incidence of metachronous brain metastases from non-small cell lung cancer with improvements in multimodality treatment of newly diagnosed patients, several studies have shown that prophylactic whole brain radiation for patients with non-small cell lung cancer does not prolong overall patient survival and can have significant neurotoxicity that can impact quality of life (69). Prophylactic whole brain radiation therapy is not currently considered standard care for patients with non-small cell lung cancer.

Differential diagnosis

	• The differential diagnosis in a patient presenting with a solitary of multiple enhancing brain lesions includes primary brain tumors, abscesses, cerebral infarction, hemorrhage, and demyelinating disease.
	• For patients presenting with suspected or proven brain metastases and no previous cancer diagnosis, workup for a systemic cancer should be pursued with a focus on the lungs.

Confusing conditions

The differential diagnosis in a patient presenting with a solitary or multiple enhancing brain lesions includes primary brain tumors, abscesses, cerebral infarction, hemorrhage, and demyelinating disease. Contrast-enhanced MRI is usually able to differentiate among these possibilities and the finding of multiple lesions is strongly suggestive of metastases, particularly in a patient with a known diagnosis of cancer. However, not all brain lesions in patients with systemic cancer are metastases. In a study of patients known to have systemic cancer who had single lesions diagnosed by contrast MRI, 11% had lesions other than brain metastases when tissue was obtained (128). Half of the nonmetastatic lesions were primary brain tumors; the other half were infections. The false-positive rate for diagnosis of multiple metastases is unknown but is certainly much less than the 11% quoted for single metastases. Biopsy is the only truly reliable method of establishing the diagnosis, if there is any doubt after contrast-enhanced imaging studies.

Associated or underlying disorders

There are no specific conditions or genetic predisposition syndromes specifically associated with the development of brain metastases from a systemic malignancy.

For patients presenting with suspected or proven brain metastases and no previous cancer diagnosis, workup for a systemic cancer should be pursued with a focus on the lungs. If the primary tumor is not bronchogenic, it has probably spread to the lungs before seeding into the arterial circulation and reaching the brain. More than 60% of patients with brain metastases will have a mass demonstrated on chest radiograph, CT scan, or MR scan that is caused by either a primary lung cancer or a lung metastases from the primary located elsewhere (113). It is reasonable to perform a mammogram in women and to do a careful skin examination in all patients. A CT or MR scan of the abdomen occasionally will show an unsuspected renal or colon cancer. Whole-body FDG-PET scanning may reveal a primary tumor that goes undetected by other imaging techniques (90). The practical utility and cost effectiveness of PET scanning in this setting are not clearly known. In the few patients with brain metastases but no identifiable lesions in the lung, the pathogenesis of the brain metastases may be spread through Batson vertebral venous plexus, tumor emboli through a patent foramen ovale (paradoxical embolus), or tumor filtered through the lungs with only local or microscopic growth.

Diagnostic workup

	• Contrast-enhanced MRI remains the best diagnostic test for brain metastases.
	• Histopathologic analysis of tissue remains the gold standard for diagnosis.

The best diagnostic test for brain metastases is contrast-enhanced MRI, showing more than one lesion in up to 75% of patients. Findings that favor metastases include multiplicity of lesions, a gray-white junction location, a lesion in the border zone between two major arterial distributions, and a small tumor nidus with a large amount of associated vasogenic edema. Contrast-enhanced MRI is more sensitive than either enhanced CT scanning (including double-dose delayed contrast) or unenhanced MRI in detecting lesions. Up to one third of patients with an apparently single lesion on contrast-enhanced CT have one or more other small lesions when a contrast-enhanced MRI is obtained (143).

MRI showing large brain metastasis

T2 FLAIR and T1-post-gadolinium-enhanced MR scan showing a large hemorrhagic brain metastasis from thyroid cancer with considerable surrounding edema. (Contributed by Dr. Mariza Daras.)
MRI showing multiple brain metastases

Pre- and post-gadolinium-enhanced MR scan from a patient with breast cancer. Due to a severe contrast allergy, the patient did not initially receive gadolinium; however, with aggressive premedication, contrast was ultimately safel...

The number of brain metastases is important for treatment planning (eg, surgical resection or stereotactic radiosurgery) and, to some extent, for prognostic predictions. Techniques such as 1.5-tesla MRI with double-dose gadolinium and 2 mm cuts (55), 3.0-tesla MRI with thin cuts (139), high-dose gadolinium, or "high resolution" MRI (75) can detect additional brain metastases in approximately 20% of patients compared with "standard" 1.5-tesla MRI scanning. In one retrospective study, 3.0-tesla MRI was slightly more sensitive than 1.5-tesla MRI in detecting small brain metastases prior to stereotactic radiosurgery, but patients who had 1.5-tesla scans did not have a higher incidence of subsequent "distant brain failure" (105).

Advanced neuroimaging techniques are also being used in clinical evaluation of suspected brain metastases as MR imaging cannot always reliably distinguish a single brain metastasis from an anaplastic glioma or an abscess. MR spectroscopy and MR perfusion may be helpful in this situation. Brain metastases are generally well circumscribed, whereas anaplastic gliomas nearly always have tumor cells infiltrating beyond the limits of contrast enhancement. These differences are reflected in the "peritumoral" choline peaks on MR spectroscopy and on cerebral blood volumes (95).

Although neuroimaging can be used to identify brain lesions, it is not specific enough for definitive diagnosis, and histopathologic analysis of tissue remains the gold standard for diagnosis. As a general rule, patients should always have histologic verification of cancer, whether from an extraneural tumor or from the brain lesion itself. For patients with a previous known cancer diagnosis, biopsy of the brain lesion is usually not necessary. Factors that raise the level of uncertainty for the diagnosis of brain metastases include: systemic tumors (eg, prostate carcinoma), which do not often metastasize to the brain parenchyma; a long interval since systemic tumor diagnosis; minimal or no systemic tumor burden; and a single versus multiple brain lesions. Imaging in these circumstances is often not reliable enough to substitute for histologic verification. A role for “liquid biopsy” of cerebrospinal fluid has been suggested as a minimally invasive approach to assess the presence of characteristic genetic alterations of brain metastases (129; 17). This approach, however, still requires validation.

Management

• Treatment options for patients with brain metastases include a combination of surgical resection, radiation therapy, systemic medical therapy, and/or supportive measures including anticonvulsants and corticosteroids.

Treatment options for patients with brain metastases include a combination of surgical resection, whole brain radiotherapy, stereotactic radiosurgery, systemic medical therapy, and/or supportive measures including anticonvulsants and corticosteroids. Several factors must be considered when determining the ideal treatment for each patient, including the primary tumor histology, extent of systemic disease, anticipated survival, neurologic status at diagnosis, and the location, number, and size of metastases. There are several possible measures of treatment efficacy for patients with brain metastases, including improvement in neurologic signs and symptoms, improvement or maintenance of functional performance status, corticosteroid requirements, and radiographic tumor response. Survival after treatment of brain metastases is an easy endpoint to measure but is confounded by the fact that systemic tumor is the cause of death for most patients with brain metastases. Measuring survival is, therefore, more meaningful when the cause of death is determined to be "neurologic" or "non-neurologic." Because brain metastases in most patients arise in the setting of disseminated tumor, the goal of treatment is not necessarily to eradicate the brain lesions. Rather, treatment should be aimed at "controlling" the brain lesions, and at maintaining patients' neurologic function for as long as possible.

Corticosteroids. In the contemporary era it is no longer necessary to initiate steroids in the majority of newly diagnoses brain metastases patients. Careful consideration should be made prior to initiating steroids as they may abrogate the efficacy of immunotherapies, oft used treatments for systemic cancers. In addition, they may obfuscate the diagnosis if the patient has CNS involvement of lymphoma.

Anticonvulsants. Seizures occur in approximately 25% of patients with brain metastases and are among the presenting symptoms in 10% to 15% of patients. To date, there is no definite evidence that any particular antiepileptic drug is differentially effective for tumor-related seizures versus epilepsy caused by other structural brain lesions. In addition to their direct side effects, anticonvulsants may cause unfavorable drug interactions with dexamethasone and several chemotherapy agents. For patients taking dexamethasone or receiving chemotherapy agents metabolized by the liver, the nonenzyme-inducing antiepileptic drugs (eg, levetiracetam or lamotrigine) may offer fewer drug interactions than enzyme-inducing drugs (eg, phenytoin or carbamazepine). Valproate may inhibit the hepatic metabolism of some cancer chemotherapy drugs. For patients who do not have seizures at the time of diagnosis of brain metastases, the current (limited) information indicates that prophylactic anticonvulsants do not reduce the incidence of subsequent seizures (65).

Surgical resection. The role of surgery in the treatment of brain metastases has been well established and can be useful for histologic confirmation, genetic profiling, cerebral decompression, reducing symptomatic mass effect/edema, and prolonging survival.

MRI showing single metastasis from lung adenocarcinoma

Gadolinium-enhanced MR scan showing a single surgically accessible right frontal metastasis from lung adenocarcinoma. (Contributed by Dr. Mariza Daras.)

Three prospective randomized trials assessed the value of aggressive local management through surgical removal of single brain metastases (128; 169; 116). In each study, patients with a single brain metastasis were treated either with complete surgical resection plus whole brain radiation therapy or with whole brain radiation therapy alone. In the study by Patchell and colleagues, patients in the surgery group had significantly longer overall survival, longer time to recurrence of brain metastases, longer duration of functional independence, and lower risk of death due to neurologic causes (128). The results of the other two studies were less decisive, but taken together, these studies have generally been interpreted to show that surgical resection is beneficial in select patients.

The value of surgery in the management of patients with multiple metastases is more controversial. In some patients with multiple metastases, there is one lesion that is large or is in a life-threatening location (eg, in the posterior fossa). For these patients, resection of one lesion can improve neurologic function and "buy time" for therapy of the other metastases. Another approach is to resect more than one brain metastasis, either as a single operation or as a stage procedure. Retrospective studies suggest that the postoperative morbidity and mortality rates for patients who undergo resection of multiple metastases are relatively low and are comparable with that reported in patients with single surgically resected metastases (15; 174). The impact of resection of multiple metastases on patients' neurologic function, quality of life, tumor control, and survival is not clear. It is not known how this treatment approach compares to "standard" whole brain radiation therapy (WBRT) or to stereotactic radiosurgery.

For most patients with brain metastases, surgical resection is not an option because of the presence of multiple lesions, extensive systemic disease and associated medical complications, or the involvement of deep-seated eloquent areas of the brain. Furthermore, surgery alone has been shown to be insufficient in achieving long-term local control (110).

Radiation therapy: whole brain radiation. Historically, whole brain radiation therapy was the standard treatment for patients with brain metastases and remains quite common. The use of whole brain radiation therapy is due in large part to a phase III study that showed whole brain radiation therapy following surgical resection reduced the rate of local and distant metastatic recurrence compared to postoperative observation alone (127).

Whole brain radiation therapy is usually given as 3000 to 4000 cGy in 10 to 15 daily fractions. Several randomized studies of altered dose/fractionation regimens have not shown any significant advantage in terms of radiographic response rates, local tumor control rates, or patient outcomes compared with "standard" 3000 cGy in 10 fractions or a biologically equivalent dose. There are surprisingly few good studies looking at the radiographic response of brain metastases to whole brain radiation therapy. Among solid tumors, metastases from breast and small cell lung carcinoma show the highest rate of radiographic response, whereas metastases from melanoma and renal carcinoma may stabilize but do not often shrink after whole brain radiation therapy (125). Other solid tumors show an intermediate radioresponsiveness. For any tumor histology, smaller metastases are more likely to regress after whole brain radiation therapy than larger lesions.

Although whole brain radiation therapy is still preferred in patients with numerous brain metastases, leptomeningeal metastasis, or primary histologies prone to micrometastatic disease such as small-cell lung cancer, treatment paradigms are changing as late delayed radiation induced neurotoxicity is being increasingly recognized. Whole brain radiation therapy may cause clinically significant diffuse brain injury. At least one half of patients with brain metastases who survive more than one year after 3000 to 4000 cGy of whole brain radiation therapy develop changes on serial CT or MRI scans, including diffuse cerebral atrophy, ventricular enlargement, and hyperintense T2-weighted or FLAIR signal abnormalities in the hemispheric white matter (45; 147; 120). A small proportion of long-term survivors with brain metastases develop progressive dementia, psychomotor retardation, gait disturbance, and urinary incontinence, appearing 6 to 18 months after whole brain radiation therapy (45; 48). The incidence of "radiation therapy dementia" is not clearly known; a disproportionately high percentage of reported patients received daily dose fractions greater than 300 cGy. The clinical similarity of this syndrome to normal pressure hydrocephalus has led some patients to undergo ventriculoperitoneal cerebrospinal fluid shunting, which can produce partial improvement in some patients. To date, however, there is no reliable way to predict which patients would benefit from a shunt.

Current data suggest that inadequate control or recurrence of brain metastases is a more common cause of deteriorating neurocognitive function than is the toxicity of whole brain radiation, and whole brain radiation remains an important part of treatment for some patients (97). As a result, strategies to minimize long-term neurocognitive deficits include the use of intensity-modulated radiation therapy to deliver "whole-brain" treatment while sparing the hippocampi (68), as well as neuroprotective agents such as memantine given during the course of whole brain radiation therapy and for a total of six months (23). The contemporary NRG cooperative group CC001 randomized phase 3 trial combined both approaches with additive benefit in preventing neurocognitive deterioration (21). In more recent years, radiotherapy has also moved toward more localized techniques such as stereotactic radiosurgery.

Stereotactic radiosurgery. Stereotactic radiosurgery as a monotherapy has become increasingly popular in recent years for patients with limited brain disease as a way to largely spare normal brain. The technique uses a linear accelerator or multiple Cobalt-60 sources ("gamma knife") to deliver a highly focused single dose of radiation (usually 1000 to 2000 cGy) to a circumscribed target. Brain metastases are theoretically well suited for radiosurgery because they are usually roughly spherical and well circumscribed.

Radiosurgery has been administered to a large number of patients in a number of settings: as primary treatment of single metastases instead of surgical resection; as the sole treatment of newly diagnosed single or multiple brain metastases; in combination with whole brain radiation therapy for newly diagnosed metastases; and as treatment of recurrent brain metastases. Numerous retrospective series of stereotactic radiosurgery have reported "local control" rates as high as 75% to 95%, ie, radiographic shrinkage or stabilization of treated lesion(s) for the lifetime of the patient (07; 146; 100). Tumors such as melanoma and renal carcinoma, which are considered "radioresistant," have a better local control rate from radiosurgery than from whole brain radiation (94; 30; 99). Larger metastases generally have lower radiographic control rates than smaller lesions, which is partly related to the ability to safely administer a higher tumor margin dose for metastases smaller than 2cm (29; 30). For patients with multiple metastases, the local control rate is probably related more to the total volume of treated tumor than to the number of metastases (99; 100). In most centers the maximum tumor size for single-fraction radiosurgery is 3 cm. Large retrospective cohort studies have demonstrated excellent local control for tumors less than or equal to 2 cm treated with 2400 cGy single-296 fraction stereotactic radiosurgery alone. However, metastases of 2 cm or greater treated with single-fraction stereotactic radiosurgery doses of 1500 to 1800 cGy 297 have been associated with poor local control and multifractionated stereotactic radiosurgery is recommended for tumors 3 cm or greater (40).

Several studies have compared stereotactic radiosurgery alone versus stereotactic radiosurgery and whole brain radiation therapy in patients with oligometastatic disease (up to three brain metastases) and showed no significant difference in overall survival with the omission of whole brain radiation therapy (03; 04; 92). Although local and distant control improved with the combination, neurocognitive function is retained with stereotactic radiosurgery monotherapy (31; 22). As a result, it is recommended whole brain radiation therapy not be routinely added to stereotactic radiosurgery for the treatment of limited numbers of brain metastases.

The low risk of complications associated with stereotactic radiosurgery and the ability to perform stereotactic radiosurgery on an outpatient basis offers potential cost savings and safety advantages over conventional surgical resection for the treatment of cerebral metastases. Most comparisons of patients with a single, newly diagnosed surgically resectable brain metastasis showed that stereotactic radiosurgery produced local tumor control rates generally equivalent to those seen after surgical resection (07; 134; 135; 122). In one retrospective study, surgical resection yielded better local control and survival than radiosurgery (14). Surgical resection does offer the advantage of immediate debulking and relief of symptoms due to mass effect, and it can deal with metastases too large to be suitable for radiosurgery.

An increasingly utilized approach is a resection of the single brain metastasis and then give stereotactic radiosurgery to the margins of the resection cavity. In several series, this combined treatment resulted in 1-year local control rates of 70% to 90% (85; 38; 110). Local control rates after single-fraction radiosurgery are lower if the resection cavity is large or its margins are indistinct. Hypofractionated radiosurgery can be used for postoperative treatment of a large (eg, greater than 3 cm) resection cavity; however, specific patient selection criteria and treatment dosimetry are not well established.

Several studies have also looked at the efficacy of stereotactic radiosurgery for patients with more than four brain metastases and suggest that stereotactic radiosurgery alone may be a reasonable approach for patients with multiple metastases. A large prospective observational study by Yamamoto and colleagues for patients undergoing stereotactic radiosurgery for 1 to 10 metastases found similar survival outcomes for patients with two to four versus five to 10 metastases (177), and the aggregate volume of lesions being treated may be more important in predicting the efficacy of stereotactic radiosurgery (101). A phase 3 randomized control trial comparing stereotactic radiosurgery versus whole brain radiation in patients with five to 15 intact brain metastases was completed and found in nonmelanoma patients with four to 15 metastases, and stereotactic radiosurgery was associated with reduced cognitive deterioration compared to whole brain radiation without compromising OS (98). However, the recommendation for stereotactic radiosurgery for patients with brain metastases is determined not only by the number of brain metastases but by other patient-related factors. These include tumor size, location, brain metastasis velocity, histology, age, functional status, extent of extra cranial disease, molecular profile, systemic treatment options, and overall prognosis.

The acute toxicity of radiosurgery includes transient worsening of neurologic deficits and increased peritumoral edema, occurring in approximately 5% of patients within several days after treatment (146; 132). The symptoms improve with corticosteroids. Five percent to 10% of patients develop symptomatic or asymptomatic radiographic worsening (increased contrast enhancement and increased edema) 3 to 6 months after radiosurgery. Most patients subsequently show clinical and radiographic improvement over the subsequent few months. Intratumoral hemorrhage may occur following radiosurgery, particularly with melanoma (30; 99). Delayed symptomatic focal brain necrosis occurs in 2% to 5% of treated patients (146; 131). The incidence of symptomatic radiation necrosis may be higher after treatment of larger versus smaller metastases (16). Symptomatic cyst formation occasionally occurs in long-term survivors after radiosurgery. In a long-term follow-up study of patients who survived at least 3 years after radiosurgery for brain metastases, solid mass lesions or cysts developed at the treatment site with an actuarial incidence of 4% at five years and 21% at 10 years (176).

The practical difficulty in the patients treated with stereotactic radiosurgery is distinguishing radiation injury from tumor progression or from the common coexistence of necrosis and viable tumor using standard diagnostic MRI scans. Fluorodeoxyglucose-PET scanning (171; 81), MR spectroscopy, or perfusion MRI (78; 118) have fairly good reliability, particularly in cases of “pure” necrosis or “pure” tumor, but all have false positives and false negatives.

Chemotherapy. Cytotoxic chemotherapy has generally not been highly successful in treating brain metastases due to several factors: (1) several common sources of brain metastases are not sensitive to currently available agents; (2) many patients who develop brain metastases have already "failed" one or more chemotherapy regimens; (3) subclones of tumor cells that metastasize may be inherently less chemosensitive than the cells in the primary tumor; and (4) the blood-brain barrier may limit penetration of water-soluble agents and macromolecules into brain metastases. These difficulties were highlighted in a study of patients with newly diagnosed small cell lung cancer, considered a "chemosensitive" tumor: 73% of patients had a systemic response to initial chemotherapy, but only 29% of patients with asymptomatic brain metastases showed a neuroimaging response to the same chemotherapy (144). Similarly, for patients with brain metastases from melanoma, conventional systemic chemotherapeutic options have shown very limited efficacy with radiographic response rates of 0% to 10% and tumor stabilization rates of 10% to 30% (93; 06).

Despite these serious limitations, chemotherapy may have a role in the treatment of selected patients. Some patients with chemosensitive tumors (eg, breast, small cell lung cancer, germ cell tumors) respond to systemic chemotherapy, either as initial therapy for previously untreated brain metastases (57; 33; 73) or for recurrence of brain metastases after prior whole brain radiation therapy (18; 54). For patients with breast cancer, the choice of systemic therapy is often driven by the subtype: with brain metastases from triple negative breast cancer, capecitabine has shown benefit (54), and for estrogen or progesterone receptor positive breast cancer, hormonal therapies are primarily utilized (141; 162; 53). For most patients with germ cell tumors, chemotherapy without cranial irradiation is effective in treating brain metastases, but a small minority of patients have isolated relapse of brain metastases despite eradication of systemic tumor (09). Carboplatin plus pemetrexed has shown modest activity as first-line therapy for brain metastases from lung adenocarcinoma, as well as combinations of vinorelbine, cisplatin, and paclitaxel (137; 42; 11; 47).

Molecular targeted agents. As targeted agents are becoming an important part of standard initial therapy for the management of systemic cancer, the utility of these agents for the treatment of brain metastases has also become increasingly evident.

Several targeted agents have become first-line standard of care for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations and have shown significant benefit in CNS disease management. Specifically in epidermal growth factor receptor-mutant non-small cell lung cancer brain metastases, first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have demonstrated response rates of 50% to 80%, overall survival of 15 to 22 months, and increased efficacy with pulsatile high dose administration (28; 82; 148; 89; 74; 172; 83). In one nonrandomized retrospective series, patients with advanced-stage epidermal growth factor receptor-mutant non-small cell lung cancer treated with gefitinib or erlotinib had a lower risk of developing brain metastases than similar patients treated with cytotoxic chemotherapy (76). More recently due to improved CNS penetration, durable response, and efficacy in patients with progression after treatment with first generation tyrosine kinase inhibitors, the second-generation tyrosine kinase inhibitor osimertinib is now considered first-line therapy for patients with EGFR-mutant NSCLC, particularly for those with brain metastases. It can also be considered for the primary prevention of brain metastases compared with first-generation tyrosine kinase inhibitors (119; 154). For anaplastic lymphoma kinase (ALK)-positive, anaplastic lymphoma kinase inhibition is a viable option. The first-generation anaplastic lymphoma kinase inhibitor crizotinib has limited blood-brain barrier penetration. For patients with brain metastases, second and third-generation anaplastic lymphoma kinase inhibitors, such as alectinib, brigatinib, ceritinib, and lorlatinib, have shown superior activity even in an anaplastic lymphoma kinase-inhibitor-pretreated patient, with response rates up to 81%, and they are preferred (152; 153; 27; 60). For patients with ROS1 translocations, entrectininb has shown CNS activity in crizotinib-naïve disease with overall response rates of 79% (52). For RET fusion-positive NSCLC, selpercatinib has shown benefit in patients with brain metastases (50; 163).

For patients with breast cancer-related brain metastases, treatment is dependent on the presence of HER-2 and/or hormone receptor expression. The occurrence of isolated brain metastases in patients with HER-2-expressing breast cancer treated with the monoclonal antibody trastuzumab is at least partly due to the inability of trastuzumab to cross the blood-brain barrier. Small molecule inhibitors of the HER-2 tyrosine kinase, such as lapatinib, have shown modest activity against breast cancer brain metastases (104; 164). Cyclin-dependent kinase (CDK) inhibitors specifically targeting CDK4/6 have become an important part of treatment for hormone receptor-positive breast cancer. Abemaciclib, with the highest CNS penetration, has shown promise in the treatment of brain metastases with intracranial benefit of 24% (166).

CNS penetrant chemotherapy-targeted drug combinations and drug conjugates are increasingly showing efficacy in the management of breast cancer-related brain metastases in patients with breast cancer and brain metastases. A phase 2 study of lapatinib plus capecitabine (LANDSCAPE) for previously untreated brain metastases from breast cancer showed a 66% radiographic response rate (10). Although neratinib alone demonstrated limited efficacy, the combination with capecitabine yielded a 49% response rate (58; 59). Similar results have been seen with TDM1, tucatinib/trastuzumab/capecitabine (HER2CLIMB), fam-trastuzumab deruxtecan (DEBBRAH), and sacituzumab govitecan for triple negative breast cancer (ASCENT) (102; 121; 12; 130). In the phase 3 HER2CLIMB study, for patients with HER2-positive breast cancer with brain metastases treated with trastuzumab/capecitabine and the addition of tucantinib, intracranial overall response rates doubled, the risk of intracranial progression or death was reduced by 68%, and the risk of death was reduced by 42% when compared to trastuzumab and capecitabine alone (102; 121).

Targeted therapies have also altered the treatment paradigm for metastatic melanoma. Vemurafenib is a signal transduction inhibitor that acts on BRAF kinase and has shown effectiveness in some patients with brain metastases from melanoma (114). Dabrafenib is another BRAF inhibitor that produced an objective radiographic response in one third of melanoma brain metastases in patients whose tumors had the Val600Glu BRAF mutation (107). The combination of dabrafenib and the mitogen-activated protein kinase (MAPK) inhibitor trametinib has yielded improved intracranial response rates, as have combinations of vemurafenib and cobimetinib or encorafenib and binimetinib. Intracranial overall response rates with these agents ranges between 33% to 43%, intracranial disease control rate between 60 and 79%, and mOS between 9.5 and 11.2 months (64; 49; 79). However, duration of response remains a problem (43). Combination with immunotherapy has not shown improved duration of response, and a phase 2 study of atezolizumab, vemurafenib, and cobimetinib (TRILOCET) resulted in an intracranial response rate of 42%, but PFS was five months, and duration of response was seven months (51). In addition, combination of these targeted therapies with stereotactic radiosurgery may have additional benefit (108).

In patients with renal cell carcinoma, the VEGFR tyrosine kinase inhibitor cabozantinib has shown early signs of efficacy in patients with brain metastases with a reported intracranial response rate of 61% (77). There are also reports of radiographic response of brain metastases from renal carcinoma to the oral multikinase inhibitors sorafenib (168) or sunitinib (70). However, only one prospective study, a phase 2 trial of sunitinib in patients with untreated brain metastases, has examined the CNS efficacy of VEGFR tyrosine kinase inhibitors in patients with mRCC. Among 16 evaluable patients, the CNS response rate was 0% and the percentage of patients with stable disease was 31%. The median time to progression was 2.3 months and the median overall survival was 6.3 months (36). In one study of patients with renal carcinoma and brain metastases treated with stereotactic radiosurgery, those who were also treated with a tyrosine-kinase inhibitor, mTOR inhibitor, or bevacizumab had a better rate of local control of the brain lesions compared to patients who did not receive targeted therapy (39).

Immunotherapy. To date, immunotherapy for brain metastases mainly applies to melanoma and non-small cell lung cancer. Immune checkpoint inhibitors targeting CTLA-4 (ipilimumab), PD-1 (nivolumab, ipilimumab), and PD-L1 (atezolizumab), all of which act to augment T-lymphocyte activation, have shown benefit in the treatment of melanoma and non-small cell lung cancer-related brain metastases (109). Disease control rates of melanoma brain metastases with single agent ipilimumab or pembrolizumab have ranged from 10% to 22% with sustained response, and combination therapy has shown even higher response rates near 60% with a marked increase in survival (111; 67; 106; 165). In patients with non-small cell lung cancer treated with single-agent pembrolizumab, intracranial response rates reached 33% and were durable in most patients, with CNS PFS of 10.7 months and mOS of 8.9 months (67; 66). Single agent atezolizumab in patients with asymptomatic treated non-small cell lung cancer brain metastases was associated with improved survival when compared to traditional chemotherapy (61). It is not yet clear how ipilimumab should be integrated into the overall treatment strategy of patients with brain metastases, and exploration of combined regimens of radiation therapy and immunotherapy have been pursued and are suggestive of a synergistic benefit (02; 123). Alternative approaches include treatment with autologous tumor-infiltrating lymphocytes engineered to express a T-lymphocyte receptor that recognizes a melanocytic differentiation antigen has also caused regression of brain metastases in some patients with melanoma brain metastases (80). Studies are ongoing to better explore and better understand the optimal combinations, timing of treatment, and mechanisms involved in immune activation.

Recurrent brain metastases. A difficult and frequently encountered clinical problem is the treatment of recurrent brain metastases. The reappearance of brain metastases is often complicated by the fact that many of these patients also have extensive systemic disease. In general, the same types of treatment used for newly diagnosed brain metastases are also available for recurrent tumors. However, the type of previous therapy often limits the therapeutic options available at recurrence.

Surgical resection of recurrent brain metastases is an option for selected patients with a single site of brain recurrence, limited systemic disease, and a fairly good performance status. This includes patients who received prior resection, whole brain radiation, or radiosurgery (167; 86).

For patients with recurrence of brain metastases after whole brain radiation therapy, the amount of additional radiation therapy that can be given safely is usually 1500 to 2500 cGy. Repeat courses of whole brain radiation therapy can improve or stabilize neurologic function in a significant proportion of patients (173; 140). Reirradiation may be somewhat more beneficial in the subset of patients who showed an initial favorable response to radiation therapy and who remain in good general condition when the cerebral recurrence develops (41). Systemic tumor status is the main determinant of survival for these patients.

Several series of patients with recurrent brain metastases following whole-brain radiation and subsequent radiosurgery have shown high rates of local control over the patients' lifetimes (34; 32; 25). Longer overall survival is correlated with good performance status, "controlled" primary tumor, a single brain metastasis versus multiple metastases, and the total volume of brain lesions treated with radiosurgery (25). Despite control of the treated lesions, patients may die of leptomeningeal dissemination or "polyfocal intraparenchymal" metastases (34; 131).

Novel approaches: laser interstitial therapy (LITT). Stereotactic laser ablation, or laser interstitial therapy, is one of the newer and innovative techniques that has emerged for recurrent brain metastases and radiation necrosis. It involves a small burr hole through which a biopsy is simultaneously obtained and treatment is delivered through using a laser probe. Although there are limitations on lesional size and posttreatment related edema, this technique allows for treatment of deep-seated lesions that may not be accessible for resection, as well previously irradiated areas. Small prospective studies have shown some benefit, but more rigorous prospective randomized studies are still needed (01; 136; 145).

Follow-up. There is no set standard for the follow-up of brain metastases after treatment. Clearly, MRI or CT scans are indicated at any time after therapy where patients develop new neurologic symptoms. How frequently asymptomatic patients need follow-up scans is controversial. For patients treated with surgery, a contrast MRI scan should be performed within five days after surgery to detect residual disease. This is especially important if consideration is being made to forgo postoperative whole brain radiation therapy. A reasonable schedule of follow-up scanning would be to get a scan 2 to 3 months after completion of last therapy (either whole brain radiation therapy, surgery, or radiosurgery), and then about every 2 to 3 months for the first year following treatment. The length of time between scans can then be gradually stretched out so that asymptomatic patients are scanned only once per year.

Outcomes

Median survival for patients with brain metastases varies widely for patients with non-small cell lung, breast, melanoma, gastrointestinal, and renal cancers (see Prognosis and complications). Outcomes are largely dependent on a number of variables that include age, functional status, extent of systemic and CNS disease, CNS disease velocity, and molecular profiling. Improved radiation techniques and developments in targeted therapies and immunotherapies for patients with non-small cell lung cancer, breast cancer, and melanoma have dramatically transformed the treatment and survival of patients with brain metastases. As patients live longer with CNS metastatic disease, however, in addition to side effects such radiation necrosis discussed earlier, cognitive impairment as a direct effect of metastatic disease as well as an effect of therapy remains a challenge. Up to 30% of patients with cancer exhibit cognitive impairment prior to treatment, 75% might have measurable cognitive impairment during treatment, and 35% of cancer survivors will continue to exhibit cognitive difficulties in the months to years that follow treatment (84).

Media

References

01: Ahluwalia M, Barnett GH, Deng D, et al. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg 2018;130(3):804-11. PMID 29726782
02: Anderson ES, Postow MA, Wolchok JD, et al. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer 2017;5(1):76. PMID 29037215
03: Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-72. PMID 15158627
04: Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J Amer Med Assoc 2006;295(1):2483-91. PMID 16757720
05: Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-90. PMID 7707405
06: Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008;113(8):2139-45. PMID 18792064
07: Auchter RM, Lamond JP, Alexander E, et al. A multi institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Rad Oncol Biol Phys 1996;35:27-35.
08: Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New Engl J Med 1999;341:476-84. PMID 10441603
09: Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumor. Int J Radiat Oncol Biol Phys 2007;69(1):163-6. PMID 17707269
10: Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer. Lancet Oncol 2013;14:64-71. PMID 23122784
11: Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 2012;14:491-5. PMID 22362813
12: Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384(16):1529-41. PMID 33882206
13: Barnholtz JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastases. Neuro Oncol 2012;14:910-8. PMID 22544733
14: Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 1996;84:748-54. PMID 8622147
15: Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79:210-6. PMID 8331402
16: Blonigen BJ, Steinmetz RD, Levin L, et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Rad Oncol Biol Phys 2010;77:996-1001.
17: Boire A, Brandsma D, Brastianos PK, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 2019;21(5):571-84. PMID 30668804
18: Boogerd W, Dalesio O, Bais EM, van der Sande J. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-80. PMID 1735089
19: Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer 1997;79(2):403-10. PMID 9010115
20: Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015;5(11):1164-77.** PMID 26410082
21: Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol 2020;38(10):1019-29. PMID 32058845
22: Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016;316(4):401-9.** PMID 27458945
23: Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neurooncol 2013;15(10):1429-37. PMID 23956241
24: Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011;17:4834-43. PMID 21768129
25: Caballero JA, Sneed PK, Lamborn KR, et al. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Rad Oncol Biol Phys 2012;83:303-9.
26: Carvalho R, Paredes J, Ribeiro AS. Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling. Semin Cancer Biol 2020;60:294-301. PMID 31711993
27: Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Eng J Med 2018;379(21):2027-39. PMID 30280657
28: Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann Oncol 2004;15(7):1042-7. PMID 15205197
29: Chang EL, Hassenbusch SJ 3rd, Shiu AS, et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003;53(2):272-80; discussion 280-1. PMID 12925241
30: Chang EL, Selek U, Hassenbusch SJ, et al. Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005;56(5):936-45. PMID 15854241
31: Chang EL, Wefel JS, Kess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037-44. PMID 19801201
32: Chao ST, Barnett GH, Vogelbaum MA, et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer 2008;113(8):2198-204. PMID 18780319
33: Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer 2008;9(1):35-8. PMID 18282356
34: Chen JC, Petrovich Z, Gianotta SL, Yu C, Apuzzo ML. Radiosurgical salvage therapy for patients presenting with recurrence of metastatic disease to the brain. Neurosurgery 2000b;46:860-6. PMID 10764259
35: Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 2016;533(7604):493-8. PMID 27225120
36: Chevreau C, Ravaud A, Escudier B, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 2014;12(1):50-4. PMID 24268852
37: Chidel MA, Suh JH, Reddy CA, et al. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2000;47:993-9. PMID 10863070
38: Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Rad Oncol Biol Phys 2012;84(2):336-42. PMID 22652105
39: Cochran DC, Chan MD, Aklilu M, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with gamma knife surgery. J Neurosurg 2012;116:978-83. PMID 22385005
40: Cohen-Inbar O, Sheehan JP. The role of stereotactic radiosurgery and whole brain radiation therapy as primary treatment in the treatment of patients with brain oligometastases -- a systematic review. J Radiosurg SBRT 2016;4(2):79-88. PMID 29296432
41: Cooper JS, Steinfeld AD, Lerch IA. Cerebral metastases: value of reirradiation in selected patients. Radiology 1990;174:883-5. PMID 2305074
42: Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003;64(1):28-35. PMID 12457029
43: Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicenter, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73.** PMID 28592387
44: Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 2012;118:4652-9. PMID 22359359
45: DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989a;39:789-96. PMID 2725874
46: DeAngelis LM, Posner JB. Intracranial metastases. In: DeAngelis LM, Posner JB, editors. Neurologic complications of cancer. New York: Oxford University Press, 2009:141-93.
47: Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X, Chen LK. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol 2013;112(3):461-6. PMID 23420398
48: Doyle DM, Einhorn LH. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 2008;70(5):1361-4. PMID 18374223
49: Drago JZ, Lawrence D, Livingstone E, et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Res 2019;29(1):65-9. PMID 30376465
50: Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813-24. PMID 32846060
51: Dummer R, Queirolo P, Abajo Guijarro AM, et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2022;23(9):1145-55. PMID 35940183
52: Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol 2021;39(11):1253-63. PMID 33646820
53: Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008;112(11):2359-67. PMID 18361426
54: Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007;85(2):223-7. PMID 17611719
55: Engh JA, Flickinger JC, Niranjan A, Amin DV, Kondziolka DS, Lunsford LD. Optimizing intracranial metastasis detection for stereotactic radiosurgery. Stereotact Funct Neurosurg 2007;85(4):162-8. PMID 17259753
56: Farris M, McTyre ER, Cramer CK, et al. Brain metastasis velocity: a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone. Int J Radiat Oncol Biol Phys 2017;98(1):131-41. PMID 28586952
57: Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599-605. PMID 10193952
58: Freedman RA, Gelman RS, Wefel JS, et al. Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 2016;34(9):945-52. PMID 26834058
59: Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib fir patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 2019;37(13):1081-9. PMID 30860945
60: Gadgeel S, Peters S, Shaw AT, et al. Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 2018;29(11):2214-22. PMID 30215676
61: Gadgeel SM, Lukas RV, Goldschmidt J, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer 2019;128:105-12. PMID 30642441
62: Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-6. PMID 10863071
63: Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51. PMID 9128946
64: Geukes Foppen MH, Boogerd W, Blank CU, et al. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Res 2018;28(2):126-33. PMID 29356790
65: Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93. PMID 10822423
66: Goldberg S, Gettinger S, Mahajan A, et al. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. J Clin Oncol 2018;36(15_suppl):2009-2009.
67: Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomized, open-label, phase 2 trial. Lancet Oncol 2016;17(7):976-83. PMID 27267608
68: Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014;32(34):3810-16. PMID 25349290
69: Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011a;29(3):272-8. PMID 21135270
70: Gore EM, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011b;117:501-9. PMID 20862748
71: Grant FC. Concerning intracranial malignant metastases: their frequency and the value of surgery in their treatment. Ann Surg 1926;84:635-46.
72: Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997;33:1752-8. PMID 9470828
73: Gremmer R, Schroder ML, Ten Huinink WW, Brandsma D, Boogerd W. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 2008;90(3):335-9. PMID 18704268
74: Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-9.** PMID 21865399
75: Hanssens P, Karlsson B, Yeo TT, et al. Detection of brain micrometastases by high-resolution stereotactic MRI and its impact on the timing of and risk for distant recurrences. J Neurosurg 2011;115:499-504. PMID 21639696
76: Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on CNS progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012;18:4406-14. PMID 22733536
77: Hirsch L, Chanza NM, Farah S, et al. Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): an international multicenter study. J Clin Oncol 2021;39(suppl 6).
78: Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009;256(6):878-87. PMID 19274425
79: Holbrook K, Lutzky J, Davies MA, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. Cancer 2020;126:523-30. PMID 31658370
80: Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010;16(19):4892-8. PMID 20719934
81: Horky LL, Hsiao EM, Weiss SE, et al. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neuro Oncol 2011;103:137-46.
82: Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46(2):255-61. PMID 15474674
83: How J, Mann J, Laczniak AN, Baggstrom MQ. Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of literature. Clin Lung Cancer 2017;18(4):354-63. PMID 28245967
84: Janelsins M, Kesler S, Ahles T, Morrow G. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014;26:102-13. PMID 24716504
85: Jensen CA, Chan MD, McCoy TP, et al. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 2011;114(6):1585-91. PMID 21166567
86: Kano H, Kondziolka D, Zorro O, et al. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 2009;111:825-831. PMID 19425892
87: Kebudi R, Ayan I, Gorgun O, Agaoglu FY, Vural S, Darendeliler E. Brain metastases in pediatric extracranial solid tumors: survey and literature review. J Neurooncol 2005;71(1):43-8. PMID 15719274
88: Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-77. PMID 20498394
89: Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009;65:351-4. PMID 19157632
90: Klee B, Law I, Hojgaard L, Kosteljanetz M. Detection of unknown primary tumours in patients with cerebral metastases using whole-body fluorodeoxyglucose positron emission tomography. Eur J Neurol 2002;9(6):657-62. PMID 12453082
91: Klemm F, Maas RR, Bowman RL, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 2020;181(7):1643-1660.e17. PMID 32470396
92: Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29(2):134-41. PMID 21041710
93: Larkin JM, Hughes SA, Beirne DA, et al. A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007;96(1):44-8. PMID 17146474
94: Lavine SD, Petrovich Z, Cohen-Gadol AA, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999;44:59-66. PMID 9894964
95: Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715-21. PMID 11867790
96: Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27(31):5278-86. PMID 19770385
97: Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25(10):1260-6.** PMID 17401015
98: Li J, EB Ludmir, Y Wang, et al. Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: a phase III randomized controlled trial. Int J Rad Oncol 2020;108(3, Supplement):S21-2.
99: Liew DN, Kano HK, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011;114(3):769-79. PMID 20524829
100: Likhacheva A, Pinnix CC, Parikh NR, et al. Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Rad Oncol Biol Phys 2013;85:656-61.
101: Limon D, McSherry F, Herndon J, et al. Single fraction stereotactic radiosurgery for multiple brain metastases. Adv Radiat Oncol 2017;2(4):555-63. PMID 29204522
102: Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610-9.** PMID 32468955
103: Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113(10):2638-45. PMID 18833576
104: Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15(4):1452-9. PMID 19228746
105: Loganathan AG, Chan MD, Alphonse N, et al. Clinical outcomes of brain metastases treated with gamma knife radiosurgery with 3.0 T versus 1.5 T MRI-based treatment planning: have we finally optimised detection of occult brain metastases. J Med Imaging Rad Oncol 2012;56:554-60.
106: Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the anti-PD1 brain collaboration (ABC). J Clin Oncol 2017;35(Suppl_15):9508.
107: Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain: a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-95. PMID 23051966
108: Lukas RV. Commentary: BRAF V600 mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study. Neurosurgery 2019;84(4):881-2. PMID 29846721
109: Lukas RV. Commentary: immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons. Neurosurgery 2020;87(3):E289-90. PMID 32302397
110: Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18(8):1040-48. PMID 28687375
111: Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-65. PMID 22456429
112: Marko NF, Xu Z, Gao T, et al. Predicting survival in women with breast cancer and brain metastases. Cancer 2012;118:3749-57. PMID 22180078
113: Mavrakis AN, Halpern EF, Barker FG 2nd, Gonzalez RG, Henson JW. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology 2005;65(6):908-11. PMID 16186533
114: McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Ann Oncol 2017;28(3):634-41. PMID 27993793
115: McTyre ER, Soike MH, Farris M, et al. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiother Oncol 2020;142:168-74. PMID 31526671
116: Mintz AH, Kestle J, Gaspar L, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single cerebral metastasis. Cancer 1996;78:1470-6. PMID 8839553
117: Mitra D, Chen YH, Hermann G, et al. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol 2019;18:32-8. PMID 31341973
118: Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol 2010;99(1):81-8. PMID 20058049
119: Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376(7):629-40. PMID 27959700
120: Monaco EA, Faraji AH, Berkowitz O, et al. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 2013;119:226-32. PMID 22707281
121: Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 2020;31(10):1350-8. PMID 32634611
122: Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol 2008:87(3):299-307. PMID 18157648
123: Nardin C, Mateus C, Texier M, et al. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Res 2018;28(2):111-9.** PMID 29356789
124: Nguyen LN, Maor MH, Oswald MJ. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998;83(10):2181-4. PMID 9827723
125: Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997;39:25-30. PMID 9300736
126: Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years. Cancer 2011;117:2505-12. PMID 24048799
127: Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. J Amer Med Assoc 1998;280:1485-9.
128: Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. New Engl J Med 1990;322:494-500. PMID 2405271
129: Pentsova EI, Ronak SH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 2016;34(20):2404-15.** PMID 27161972
130: Perez-Garcia JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol 2023;25(1):157-66. PMID 35639825
131: Petrovich Z, Yu C, Giannotta SL, O'Day S, Apuzzo ML. Survival and pattern of failure in brain metastases treated with stereotactic gamma knife radiosurgery. J Neurosurgery 2002;97 (5 Suppl):499-506. PMID 12507085
132: Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998;16:3563-9. PMID 9817276
133: Priego N, Zhu L, Monteiro C, et al. STAT3 labels a subpopulation of reactive astrocytes required from brain metastasis. Nat Med 2018;24(7):1024-35. PMID 29892069
134: Rades D, Bohlen G, Pluemer A, et al. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer 2007c;109(12):2515-21. PMID 25076242
135: Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int J Radiat Oncol Biol Phys 2009;73(4):1077-81. PMID 18707817
136: Rennert RC, Khan U, Tatter SB, et al. Patters of clinical use of stereotactic laser ablation: analysis of a multicenter prospective registry. World Neurosurg 2018;116:e566-70. PMID 29772367
137: Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinolrelbine combination on inoperable brain metastases of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) protocol 95-1. Ann Oncol 2001;12(1):59-67. PMID 11249050
138: Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chenotherapy for operable Her2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. PMID 16236738
139: Saconn PA, Shaw EG, Chan MD, et al. Use of 3.0-T MRI for stereotactic radiosurgery planning for treatment of brain metastases: a single-institution retrospective review. Int J Radiat Oncol Biol Phys 2010;78(4):1142-6. PMID 20832185
140: Sadikov E, Bezjak A, Yi QL, et al. Value of whole brain re-irradiation for brain metastases—single centre experience. Clin Oncol (R Coll Radiol) 2007;19(7):532-8. PMID 17662582
141: Salvati M, Cervoni L, Innocenzi G, Bardella L. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori 1993;79(5):359-62. PMID 8116083
142: Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001;51:426-34. PMID 11567817
143: Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol 1999;44:275-81. PMID 10720207
144: Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006;24:2079-83. PMID 16648509
145: Shah AH, Semonche A, Eichberg DG, et al. The role of laser interstitial thermal therapy in surgical neuro-oncology: series of 100 consecutive patients. Neurosurgery. 2020 Aug 1;87(2):266-275. PMID 31742351
146: Shiau C, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 1997;37:375-83. PMID 9069310
147: Shibamoto Y, Baba F, Oda K, et al. Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys 2008;72(4):1168-73. PMID 18495375
148: Shimato S, Mitsudomi T, Kosaka T, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro-Oncology 2006;8:137-44. PMID 16510849
149: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7-34. PMID 30620402
150: Slotman B, Faivre C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. New Engl J Med 2007;357:664-72. PMID 17699816
151: Smith I, Procter M, Gelber RD, et al. 2-year followup of trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer: a randomized controlled trial. Lancet 2007;369(9555):29-36. PMID 17208639
152: Solomon BJ, Shaw AT, Ou SH, et al. Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small-cell lung cancer. J Thoracic Oncol 2017;12(11):S1756. PMID 29074098
153: Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4):a randomised, open-label, phase 3 study. Lancet 2017;389(10072):917-29. PMID 28126333
154: Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25. PMID 29151359
155: Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70(2):510-4. PMID 17931798
156: Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77(3):655-61. PMID 19942357
157: Sperduto PW, Kased N, Roberge D, et al. Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012a;30:419-25. PMID 22203767
158: Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012b;82(5):2111-7.** PMID 21497451
159: Sperduto PW, Deegan BJ, Li J, et al. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 2018;20(12):1652-60. PMID 30418657
160: Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 2020;38(32):3773-84.** PMID 32931399
161: Sperduto PE, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 2016;3(6):827-31. PMID 27892978
162: Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neurooncol 1995;24(3):299-301. PMID 7595761
163: Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res 2021;27(15):4160-7. PMID 34088726
164: Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases: the UK experience. Br J Cancer 2010;102:995-1002. PMID 20179708
165: Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379(8):722-730.** PMID 30134131
166: Tolaney SM, Sahebjam S, Le Rhun E, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone-receptor positive breast cancer. Clin Cancer Res 2020; 26(20):5310-9. PMID 32694159
167: Truong MT, St Clair EG, Donahue BR, et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery 2006;59:86-97. PMID 16823304
168: Valcamonico F, Ferrari V, Amoroso V, et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009;91(1):47-50. PMID 18712279
169: Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 1993;33(6):583-90. PMID 8498838
170: Vuong DA, Rades D, Vo SQ, Busse R. Extracranial metastatic patterns on occurrence of brain metastases. J Neurooncol 2011; 105(1):83-90. PMID 21394486
171: Wang SX, Boethius J, Ericson K. FDG-PET on irradiated brain tumor: ten years' summary. Acta Radiol 2006;47(1):85-90. PMID 16498938
172: Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013;31(7):895-902. PMID 23341526
173: Wong WW, Schild SE, Sawyer TE, et al. Analysis of outcome in patients re-irradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996;34:585-90. PMID 8621282
174: Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000;93:9-18. PMID 10883899
175: Xing F, Liu Y, Sharma S, et al. Activation of the c-MET pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res 2016;76(17):4970-80. PMID 27364556
176: Yamamoto M, Kawabe T, Higuchi Y, et al. Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases. Int J Rad Oncol Biol Phys 2013;85(1):53-60. PMID 22652110
177: Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15(4):387-95.** PMID 24621620
178: Zhao N, Wilkerson MD, Shah U, et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 2014;86(2):255-61. PMID 25224251

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Mariza Daras MD

Dr. Daras of UCSF Health has no relevant financial relationships to disclose.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Former Authors

Roy Patchell MD (original author) and Edward J Dropcho MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Secondary malignant neoplasm of brain and spinal cord: 198.3
ICD-10: Secondary malignant neoplasm of brain and cerebral meninges: C79.3
ICD-O: Neoplasm, malignant: M-8000/3

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Brain metastases

Differential Diagnosis

primary brain tumors
abscesses
cerebral infarcts
hemorrhages
demyelinating disease
- infections

Also Relevant

Brain metastases: considerations for surgical and radiosurgical treatment
Cerebrovascular complications of cancer
Headache associated with intracranial neoplasms
Radiation myelopathy

Clinical Categories

Neuro-Oncology

Web References

Clinical Trials

NIH: Metastatic Brain Tumors

Brain metastases

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Table 1. Recursive Partitioning Analysis (RPA) Classes for Persons with Brain Metastases

Table 2. Graded Prognostic Assessment (GPA) for Persons with Brain Metastases

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Overview of neuropathology updates for infiltrating gliomas

Anti-LGI1 encephalitis

CNS germinoma

Vestibular schwannoma

Circumscribed astrocytic gliomas [Brief]

Pediatric-type diffuse high-grade gliomas [Brief]

Glioneuronal and neuronal tumors [Brief]

Mesenchymal non-meningothelial tumors [Brief]

This is an article preview.
Start a Free Account
to access the full version.